CLIMB BIO, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $255.00K.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $5.00K.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $2.27M, a 329.30% increase year-over-year.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $8.65M, a 35950.00% increase year-over-year.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $65.00K, a 99.41% decline from fiscal 2024.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $10.98M, a 1205.47% increase from fiscal 2023.
- CLIMB BIO, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $841.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $255.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $65.00K 10-K · filed 2026-03-05 | |
| 2024-12-31 | $10.98M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $2.27M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $8.65M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $15.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $841.00K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $529.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $24.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |